TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Diagnostic Accuracy of Three Rings Vulvoscopy for Detection of Vulvar Dermatosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Three Rings Vulvoscopy performed at Poliklinika Harni, during the period from December 2011 - December 2016.~Ability to provide Informed Consent and complete Questionnaire.~Exclusion Criteria:~Incomplete medical records. Lack of histopathology. Vulvo-vaginal infection. Benign tumors of the vulva. Pre-/malignant conditions of the vulva.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Normal vulva (Type: PLACEBO_COMPARATOR): The Normal vulva group consisted of patients without vulvar discomfort (ISSVD Questionnaire), and without any vulvar lesion (Clinical examination) undergoing planned labioplasty. For each patient with vulvar dermatosis, the first consecutive patient with normal vulva was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology.
- Impaired vulvar skin (Type: PLACEBO_COMPARATOR): The group of Impaired vulvar skin was formed by the patients without vulvar symptoms (ISSVD Questionnaire), but with some non-specific vulvar lesions (Clinical examination) undergoing planned labioplasty, before surgery. For each patient with vulvar dermatosis, the first consecutive patient with impaired vulvar skin was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology.
- Vulvodynia (Type: PLACEBO_COMPARATOR): The Vulvodynia group consisted of patients with vulvar discomfort (ISSVD Questionnaire), who fulfilled Friedrich's criteria (Clinical examination). Non-specific lesions found with TRIV were not relevant for the diagnosis of vulvodynia. For each patient with vulvar dermatosis, the first consecutive patient with vulvodynia was taken for comparison.~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology.
- Vulvar dermatosis (Type: ACTIVE_COMPARATOR): The group of Vulvar Dermatosis was formed by the patients with vulvar discomfort (ISSVD Questionnaire) and vulvar lesion specific for dermatosis (Clinical examination).~Interventions: Three Rings Vulvoscopy, Vulvar Biopsy, and Histopathology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18~2. Able to give written informed consent for a clinical trial~3. Scheduled to undergo an autologous or an allogeneic stem cell transplantation from a sibling, related donor, or unrelated donor using a conditioning regimen containing at least 400 cGy TBI~4. Transplantation is being performed for one of the following medical conditions:~   * Acute myelogenous leukemia~  * Acute lymphoblastic leukemia~  * Chronic myelogenous leukemia in chronic, accelerated, or blastic phase~  * Myelodysplastic syndrome~  * Myeloproliferative diseases such as chronic myelomonocytic leukemia, agnogeneic myeloid metaplasia with myelofibrosis, polycythemia vera, or essential thrombocythemia~  * Hodgkin's lymphoma~  * Non-Hodgkin's lymphoma~  * Multiple myeloma~  * Chronic lymphocytic leukemia~  * Other malignancies or marrow disease such as aplastic anemia where transplant would be appropriate with approval of principal investigator~5. Patients with therapy-related AML or MDS may be included if their prior malignancy has been in remission for at least 12 months. If the remission is less than 12 months, approval of the principal investigator is required. Entry could be allowed if the malignancy is controlled and not expected to relapse e.g. localized prostate cancer treated with XRT.~6. Patients must meet all other pre-transplantation criteria of the transplant center including acceptable tests of heart, liver, kidney, and lung function (Standard screening for HSCT per PI, and co-investigators).~7. Karnofsky performance status must be ≥70%.~Exclusion Criteria:~1. TBI dose less than 400 cGY~2. Cord blood transplantation~3. HIV infection~4. Pregnancy or breastfeeding~5. Creatinine or bilirubin or ALT or AST greater than two times the upper limit of normal, unless the abnormal bilirubin is due to Gilbert's syndrome~6. Active infection requiring systemic antibiotic therapy with antibacterial, antifungal, or antiviral agents~7. Concomitant enrollment in another therapeutic clinical study except with PI approval~8. Must not have previously received eltrombopag~9. Patients with moderate or severe liver disease (ALT, AST, or bilirubin ≥ 2X the upper limit of normal, unless the abnormal bilirubin is due to Gilbert's syndrome) will be excluded~10. Patients with high risk of thromboembolism based on genetic syndromes , or past thromboembolic disease in the past 6 months will be excluded from the study, with the exception of those with catheter related clots

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than one year history of migraine~* Attacks typically mild when they begin and progress to moderate or severe~* Experience 1-4 migraine attacks per month~Exclusion Criteria:~* More than 15 headache days per month~* Heart disease~* Uncontrolled high blood pressure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active Drug
- 2 (Type: PLACEBO_COMPARATOR): Matching Pbo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Phase 1:~  * Age \>18 years~ * Calculated creatinine clearance \>70 mL/min/1.73 m2 (measured within 3 months)~ * Written informed consent~Phase 2:~* Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)~* Ability and willingness to provide informed consent~* Willing to receive protocol-specified lumbar punctures~Exclusion Criteria:~* Phase 1:~  * Symptomatic Current illness~ * Known significant, untreated health problem~ * Inability to take enteral medicine~ * Pregnant or breast feeding~ * Receiving amphotericin B therapy in past 90 days~* Phase 2:~  * Presenting Glasgow Coma Scale (GCS) \< 15~ * Received 3 or more doses of IV amphotericin therapy within last 30 days~ * Inability to take enteral (oral or nasogastric) medicine~ * Cannot or unlikely to attend regular clinic visits~ * Pregnancy or breastfeeding~ * Receiving chemotherapy or corticosteroids~ * Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)~ * Recent initiation of HIV therapy or ART class switch (within 2 weeks)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1a single ascending dose study (Type: EXPERIMENTAL): Phase IA will consist of a single ascending dose study in 9 participants to test three doses to determine the max tolerated dose.
- Phase 1b multiple day dosing (Type: EXPERIMENTAL): 9 subjects will receive the Phase Ia 100% tolerated MAT2203 dose for 7 days.
- Phase 2 safety and tolerability (Type: EXPERIMENTAL): Safety, tolerability, and microbiologic efficacy of MAT2203 among HIV-infected patients with cryptococcal meningitis compared with standard IV AMB.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment-naïve choroidal neovascularization (CNV) secondary to age-related macular degeneration (nAMD) in the study eye~* Ability to comply with the study protocol, in the investigator's judgment~* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive measures that result in failure rate \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment~* Other protocol-specified inclusion criteria may apply~Exclusion Criteria:~* Uncontrolled blood pressure, defined as systolic blood pressure \>180 millimeters of mercury (mmHg) and/or diastolic blood pressure \>100 mmHg while a patient is at rest on Day 1~* Pregnancy or breastfeeding, or intention to become pregnant during the study~* CNV due to causes other than AMD in the study eye~* Any history of macular pathology unrelated to AMD affecting vision or contributing to the presence of intraretinal or subretinal fluid in the study eye~* Any concurrent intraocular condition in the study eye that, in the opinion of the investigator, could either reduce the potential for visual improvement or require medical or surgical intervention during the study~* Uncontrolled glaucoma in the study eye~* Any prior or concomitant treatment for CNV or vitreomacular-interface abnormalities in the study eye~* Prior IVT administration of faricimab in either eye~* History of idiopathic or autoimmune-associated uveitis in either eye~* Active ocular inflammation or suspected or active ocular or periocular infection in either eye~* Other protocol-specified exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Faricimab (Type: EXPERIMENTAL): None
- Aflibercept (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect on Acetaminophen Metabolism by Liquid Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteer ages 18-40~* Not taking any chronic medications~Exclusion Criteria:~* Pregnancy~* Any history of liver disease~* Frequent alcohol use (2 or more drinks more than 4 times per week)~* Unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Acetaminophen solid formulation (Type: PLACEBO_COMPARATOR): Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
- Acetaminophen liquid formulation (Type: ACTIVE_COMPARATOR): Subjects in this arm will receive a 15mg/kg dose of a liquid acetaminophen formulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interventions to Improve Colorectal Cancer Screening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible for stool-based colorectal cancer screening, followed in primary care clinic~Exclusion Criteria:~* Need for surveillance or screening colonoscopy~* limited life expectancy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Fecal Immunochemical Tests (Type: EXPERIMENTAL): Mailed fecal immunochemical tests
- Arm 2: Fecal Occult Blood Tests (Type: EXPERIMENTAL): Mailed fecal occult blood tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* Diagnosis chronic obstructive pulmonary disease~* Relatively stable airway obstruction with post FEV1 \>=30 and \< 80% predicted normal and post FEV1/ FVC \< 70%~* Male or female patients, 40 years of age or more~* Smoking history more than 10 pack years~Exclusion criteria:~* Significant diseases other than COPD~* History of asthma~* COPD exacerbation in previous 3 months~* Completion of pulmonary rehabilitation program within previous 6 weeks or current participation in pulmonary rehabilitation program.~* Pregnant or nursing women~* Patients unable to comply with pulmonary medication restrictions

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium + olodaterol low dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium + olodaterol high dose (Type: EXPERIMENTAL): Once daily 2 puffs solution for inhalation Respimat
- tiotropium (Type: ACTIVE_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat
- placebo (Type: PLACEBO_COMPARATOR): Once daily 2 puffs solution for inhalation Respimat

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Postpartum Weight Retention in Low Income WIC Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women~* Age 18-40 years.~* Delivery within 6-52 weeks~* Exceed pre-pregnancy weight by at least 4.5 kg (10 pounds) or current body mass index (BMI) \>/= 25~* Current BMI \> 22~* English or Spanish speaking~* Has internet access at home or a landline~* Literacy of at least 5th grade reading level~* Has a cell phone~Exclusion Criteria:~* Pregnant or planning to become pregnant~* Relocating in the next year~* Serious psychological problems (untreated depression, schizophrenia, bipolar disorder) or medical problem (i.e. heart disease, cancer, renal disease and diabetes), for which physician supervision of diet and exercise prescription is needed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Group (Type: ACTIVE_COMPARATOR): This group will be allowed access to an online weight loss program. The program is designed to help low income women lose weight through lifestyle intervention.
- Standard WIC care (Type: NO_INTERVENTION): The control group will received Standard Care as provided through WIC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient Convenience Study (RE-SONANCE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A:~1. A. Written informed consent prior to participation~2. A. Female and male patients \>= 18 years of age with a diagnosis of non-valvular atrial fibrillation.~3. A. At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~4. A. Patients switched to Pradaxa according Summary of Product Characteristics and physician's discretion.~OR~Cohort B:~1. B. Written informed consent prior to participation.~2. B. Female and male patients \>= 18 years of age newly diagnosed with non-valvular atrial fibrillation and no previous treatment for stroke prevention (no use of any oral anticoagulant (OAC) within one year prior to enrolment).~3. B. Stroke prevention treatment initiated with Pradaxa or VKA according to Summary of Product Characteristics and physician's discretion.~Exclusion criteria:~1. Contraindication to the use of Pradaxa or VKA as described in the Summary of Product Characteristics (SmPC).~2. Patients receiving Pradaxa or VKA for any other condition than stroke prevention in atrial fibrillation.~3. Current participation in any clinical trial of a drug or device.~4. Current participation in an European registry on the use of oral anticoagulation in AF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A - VKA to Pradaxa switcher (Type: None): Patients with non-valvular atrial fibrillation (NVAF), currently on Vitamin K Antagonist (VKA) therapy, who are switched to Pradaxa.
- Cohort B - newly assigned to treatment (Type: None): Newly diagnosed NVAF patients who are treated with VKA or Pradaxa (VKA : Pradaxa = 1:1).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion criteria~* Subjects in general good health in the opinion of the investigator as determined by medical history, vital signs and a physical examination.~* Negative human leukocyte antigen (HLA) -B27 and no history of reactive arthritis~* Negative HIV, Hepatitis B and Hepatitis C serology tests.~* Blood levels of Shigella flexneri 2a LPS IgG antibodies ≤ percentile 80~* No known history of alcohol abuse~Exclusion criteria~* Subjects with a history of clinically significant gastrointestinal disorders or with any history of frequent diarrhea, nausea or emesis, regardless of etiology.~* Individuals with immunosuppressive diseases or under immunosuppressive therapy~* History of culture-proven S. flexneri.~* Individuals who have household contact with/and /or intimate exposure to an individual with laboratory confirmed S. flexneri.~* Having travelled in countries/areas highly endemic for S. flexneri within 3 months prior to enrolment.~* Previous participation in any study in which a Shigella-vaccine candidate was administered.~* Known contraindication, hypersensitivity and/or allergy to the investigational product or its excipients.~* Known hypersensitivity and/or allergy to any drug or vaccine~* Women who are pregnant or are breast-feeding, or are of childbearing age who have not used or do not plan to use acceptable birth control measures, for the duration of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- vaccine dose 1 (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 2 μg
- vaccine dose 1+ adjuvant (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 2 μg + alum
- vaccine dose 2 (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 10 μg
- vaccine dose 2 + adjuvant (Type: EXPERIMENTAL): SF2a-TT15 vaccine, 10 μg + alum
- Placebo (Type: PLACEBO_COMPARATOR): Tris buffer
- Placebo + adjuvant (Type: PLACEBO_COMPARATOR): Tris buffer + Alum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who start EYLEA treatment for Diabetic Macular Edema (DME)~Exclusion Criteria:~* Patients who have already received EYLEA treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept (Eylea,BAY86-5321) (Type: None): Decision of EYLEA treatment is made by attending investigator according to the Japanese Package Insert

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete